Drug Class Review: Targeted Immune Modulators
作者： Beth Jonas , Mark Helfand , Cecil G. Sheps , Kathleen N. Lohr , Gerald Gartlehner
DOI:
关键词: Medical encyclopedia 、 Medical education 、 Immune Modulators 、 Drug Effectiveness Review Project 、 Library science 、 Alternative medicine 、 Guideline 、 Executive summary 、 Drug class 、 Clinical effectiveness 、 Medicine
摘要: The purpose of the Executive Summary is to summarize key information contained in Drug Effectiveness Review Project report “Targeted Immune Modulators”, dated March 2012. full can be accessed at following web address: http://derp.ohsu.edu/about/final-document-display.cfm. Readers are advised review report. reports make available regarding comparative clinical effectiveness and harms different drugs. Reports not usage guidelines, nor should they read as an endorsement or recommendation for any particular drug, use, approach. They intended provide legal business advice. Oregon Health & Science University does recommend endorse guideline developed by users these reports.
参考文章(446)
Frank C Arnett, None, Revised criteria for the classification of rheumatoid arthritis. Bulletin on The Rheumatic Diseases. ,vol. 38, pp. 1- 6 ,(1989)
Alice B. Gottlieb, Psoriasis. Immunopathology and immunomodulation. Dermatologic Clinics. ,vol. 19, pp. 649- 657 ,(2001) , 10.1016/S0733-8635(05)70306-5
John Tesser, Tenshang Joh, Joy Schechtman, Alan Solinger, Dennis Modafferi, Roy Fleischmann, Ralph Bennett, Robin Dore, Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. The Journal of Rheumatology. ,vol. 31, pp. 649- 654 ,(2004)
Bernard Combe, Anouck Rémy, Jerome Avouac, Laure Gossec, Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clinical and Experimental Rheumatology. ,vol. 29, pp. 96- 103 ,(2011)
Shannon Famenini, Jashin J Wu, Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases. Journal of Drugs in Dermatology. ,vol. 12, pp. 939- ,(2013)
Der-Yuan Chen, Tsu-Yi Hsieh, Show-Jan Chou, Mariano Young, Joung-Liang Lan, Yi-Hsing Chen, A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. Journal of the Formosan Medical Association. ,vol. 103, pp. 618- 623 ,(2004)
Michael Song, Daphne Chan, Yaung-Kaung Shen, Philippe O Szapary, Lotus Investigators, Xuejun Zhu, Baoxi Wang, Min Zheng, Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). Journal of Drugs in Dermatology. ,vol. 12, pp. 166- 174 ,(2013)
Systematic Reviews in Health Care BMJ Publishing Group. ,(2001) , 10.1002/9780470693926
Bruce Strober, Marc Chevrier, Matthias Augustin, Kim A Papp, Psolar investigators, Anil Londhe, Steve Calabro, PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. Journal of Drugs in Dermatology. ,vol. 11, pp. 1210- 1217 ,(2012)
Alice B Gottlieb, Wolf-Henning Boehncke, Mohamed Darif, Safety and efficacy of alefacept in elderly patients and other special populations Journal of Drugs in Dermatology. ,vol. 4, pp. 718- 724 ,(2005)